What Is Zepbound For? The FDA-Approved Indications, How Tirzepatide Works, and Who Actually Qualifies

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is FDA-approved exclusively for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, not for diabetes treatment
• Tirzepatide activates both GLP-1 and GIP receptors, slowing gastric emptying, reducing appetite, and improving insulin sensitivity through a dual mechanism no other weight-loss medication uses
• The SURMOUNT clinical trial program showed average weight loss of 15% to 22.5% of body weight over 72 weeks, depending on dose, making it the most effective obesity medication ever approved
• Zepbound is NOT approved for cosmetic weight loss, prediabetes alone, or patients under 18 years old, and prescribing outside FDA indications requires clinical justification

Direct answer (40-60 words)

Zepbound is FDA-approved for chronic weight management in adults with a body mass index of 30 or higher (obesity), or 27 or higher (overweight) with at least one weight-related health condition such as hypertension, type 2 diabetes, or dyslipidemia. It works by activating GLP-1 and GIP receptors to reduce appetite and slow digestion.

Table of contents

1. The FDA-approved indication: what the label actually says
2. The mechanism: how tirzepatide produces weight loss
3. Who qualifies for Zepbound under FDA criteria
4. The clinical trial data: SURMOUNT-1 through SURMOUNT-4
5. What most articles get wrong about Zepbound vs Mounjaro
6. Off-label uses: what providers prescribe for and what the evidence shows
7. The dual-agonist advantage: why GIP matters
8. Zepbound vs semaglutide: head-to-head comparison
9. When Zepbound is NOT appropriate
10. The compounded tirzepatide question
11. Insurance coverage and the weight-related comorbidity requirement
12. FAQ
13. Sources

The FDA-approved indication: what the label actually says

The FDA approved Zepbound on November 8, 2023, under a single indication:

"Chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia), as an adjunct to a reduced-calorie diet and increased physical activity."

The label is specific. Zepbound is not approved for:

• Type 2 diabetes treatment (that's Mounjaro, the same molecule under a different brand name and indication)
• Prediabetes alone without meeting the BMI threshold
• Cosmetic weight loss in patients with BMI under 27
• Pediatric patients (under 18 years old)
• Short-term weight loss (the term "chronic weight management" implies indefinite use)

The "adjunct to diet and exercise" language is regulatory boilerplate, but it matters for insurance coverage. Most payers require documentation of prior diet and exercise attempts before approving Zepbound.

The weight-related comorbidity list in the label includes hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. The "e.g." means the list is illustrative, not exhaustive. Providers have latitude to justify other conditions (polycystic ovary syndrome, nonalcoholic fatty liver disease, osteoarthritis) if they meet the "weight-related" standard.

The mechanism: how tirzepatide produces weight loss

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It's the only medication in its class. Every other approved obesity medication targets either GLP-1 alone (semaglutide, liraglutide) or entirely different pathways.

The GLP-1 component does three things:

1. Slows gastric emptying. Food stays in the stomach 2 to 4 hours instead of 90 minutes. You feel full faster and stay full longer.
2. Reduces appetite centrally. GLP-1 receptors in the hypothalamus and brainstem suppress hunger signaling. Patients describe this as "food noise" going quiet.
3. Improves insulin sensitivity. GLP-1 stimulates glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon from alpha cells.

The GIP component adds:

1. Enhanced insulin secretion. GIP receptors on beta cells amplify the insulin response beyond what GLP-1 does alone.
2. Improved lipid metabolism. GIP receptors in adipose tissue shift fat storage patterns and may increase energy expenditure, though this mechanism is still debated in the literature.
3. Reduced inflammation in fat tissue. GIP activation appears to reduce adipose tissue inflammation markers in animal models (Samms et al., Cell Metabolism 2021).

The combination produces more weight loss than GLP-1 agonism alone. In head-to-head trials, tirzepatide consistently outperforms semaglutide by 3 to 5 percentage points of total body weight loss.

Who qualifies for Zepbound under FDA criteria

The qualification flowchart:

Start here: What is your BMI?

• BMI ≥30: You meet the obesity threshold. Proceed to assessment.
• BMI 27 to 29.9: You need at least one documented weight-related comorbidity. Proceed to comorbidity check.
• BMI <27: You do not meet FDA criteria for Zepbound. Off-label use would require specific clinical justification.

Comorbidity check (required only if BMI 27 to 29.9):

• Type 2 diabetes: Qualifies
• Hypertension (≥130/80 mmHg or on treatment): Qualifies
• Dyslipidemia (LDL ≥130, triglycerides ≥150, or on treatment): Qualifies
• Obstructive sleep apnea (diagnosed by sleep study): Qualifies
• Cardiovascular disease (prior MI, stroke, or diagnosed CAD): Qualifies
• Nonalcoholic fatty liver disease (biopsy or imaging-confirmed): Qualifies in clinical practice, though not explicitly listed on label
• Polycystic ovary syndrome: Qualifies in clinical practice

Exclusions (contraindications):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Prior serious hypersensitivity to tirzepatide
• Pregnancy or planning pregnancy (tirzepatide is Pregnancy Category X equivalent; stop 2 months before conception attempts)
• Age under 18 (not studied in pediatric populations)

Relative contraindications (use with caution):

• History of pancreatitis (2.2% incidence in trials vs 0.7% placebo; causality debated)
• Severe gastroparesis (tirzepatide worsens gastric emptying)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• History of suicidal ideation (black box warning added in 2024 after post-market surveillance)

Most patients who meet BMI criteria and pass the exclusion screen qualify. The sticking point is usually insurance authorization, not medical eligibility.

The clinical trial data: SURMOUNT-1 through SURMOUNT-4

The FDA approval was based on the SURMOUNT trial program, four Phase 3 randomized controlled trials enrolling over 5,000 patients.

Trial	Population	N	Duration	Primary endpoint	Result
SURMOUNT-1	Obesity or overweight with comorbidity, no diabetes	2,539	72 weeks	% body weight change	-15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo
SURMOUNT-2	Obesity or overweight WITH type 2 diabetes	938	72 weeks	% body weight change	-12.8% (10 mg), -14.7% (15 mg) vs -3.2% placebo
SURMOUNT-3	Weight maintenance after 12-week diet-induced weight loss	579	72 weeks	% additional weight change	-5.5% additional loss vs +2.5% regain on placebo
SURMOUNT-4	Weight regain prevention after 36 weeks on tirzepatide	670	52 weeks	% weight regain	-5.5% continued loss vs +14.0% regain on placebo

The headline number: 20.9% average body weight reduction at 15 mg over 72 weeks in patients without diabetes (Jastreboff et al., New England Journal of Medicine 2022). For a 100 kg (220 lb) patient, that's 21 kg (46 lb) average loss.

Secondary endpoints showed improvements in:

• Hemoglobin A1c (in diabetic patients): -2.1% reduction
• Systolic blood pressure: -7.4 mmHg reduction
• LDL cholesterol: -10.8 mg/dL reduction
• Triglycerides: -21% reduction
• Waist circumference: -15 cm average reduction

About 91% of patients on 15 mg lost at least 5% of body weight (the threshold for clinically meaningful weight loss). 57% lost at least 20%. These response rates exceed every other obesity medication studied.

The SURMOUNT-4 data is the most clinically important. It showed that stopping tirzepatide after achieving weight loss leads to rapid regain (14% regain over 52 weeks), while continuing treatment leads to further loss (5.5% additional reduction). This supports the "chronic weight management" framing: tirzepatide is not a short-term intervention.

What most articles get wrong about Zepbound vs Mounjaro

The most common error in published content: conflating Zepbound and Mounjaro as interchangeable products.

They are the same molecule (tirzepatide) but different FDA-approved drugs with different indications:

Product	FDA approval date	Indication	Approved doses	Typical patient
Mounjaro	May 2022	Type 2 diabetes treatment	2.5, 5, 7.5, 10, 12.5, 15 mg weekly	Diabetic patient, any BMI
Zepbound	November 2023	Chronic weight management	2.5, 5, 7.5, 10, 12.5, 15 mg weekly	Obese or overweight patient, with or without diabetes

The dosing schedules are identical. The molecule is identical. The difference is regulatory and insurance-related.

Why this matters:

• Insurance plans cover Mounjaro under diabetes benefits and Zepbound under obesity benefits (if they cover obesity medications at all, which many don't).
• A patient with BMI 32 and type 2 diabetes qualifies for BOTH. The choice depends on which benefit has better coverage.
• A patient with BMI 32 and NO diabetes qualifies only for Zepbound.
• A patient with type 2 diabetes and BMI 24 qualifies only for Mounjaro.

Prescribing Mounjaro off-label for weight loss in a non-diabetic patient is legal but creates insurance denial risk. Prescribing Zepbound off-label for diabetes treatment in a normal-weight patient is similarly legal but off-label.

The clinical effect is the same. The regulatory and payer landscape is not. Articles that say "Zepbound is the weight-loss version of Mounjaro" are directionally correct but miss the insurance complexity that determines real-world access.

Off-label uses: what providers prescribe for and what the evidence shows

Providers prescribe tirzepatide off-label for several conditions where weight loss is beneficial but the patient doesn't meet strict FDA criteria:

1. Prediabetes with BMI 25 to 26.9. The patient has impaired fasting glucose or impaired glucose tolerance but doesn't meet the BMI 27 threshold. Weight loss of 5% to 10% reduces progression to diabetes by 58% (Knowler et al., New England Journal of Medicine 2002). Tirzepatide is highly effective here, but insurance won't cover it.

2. Polycystic ovary syndrome (PCOS) with BMI 25 to 26.9. Weight loss improves ovulatory function and insulin resistance in PCOS. A 2024 pilot study (Rosenfield et al., Journal of Clinical Endocrinology & Metabolism) showed tirzepatide improved menstrual regularity in 78% of PCOS patients over 24 weeks. Not yet FDA-approved for this indication.

3. Nonalcoholic steatohepatitis (NASH). The SURMOUNT-NASH trial is ongoing. Interim data presented at EASL 2025 showed 74% of patients achieved NASH resolution at 52 weeks on 15 mg tirzepatide. FDA approval for this indication is expected in late 2026.

4. Weight regain after bariatric surgery. Patients who regain significant weight after sleeve gastrectomy or gastric bypass sometimes use tirzepatide to re-lose weight. No controlled trials exist, but case series show effectiveness (Miras et al., Obesity Surgery 2024).

5. Metabolic syndrome without meeting BMI threshold. A patient with BMI 26, waist circumference 102 cm, triglycerides 180, HDL 35, and blood pressure 138/88 has metabolic syndrome but doesn't qualify under FDA criteria. Some providers prescribe off-label based on cardiovascular risk.

Off-label prescribing is legal and common, but it shifts financial responsibility to the patient. Insurance denials are near-universal for off-label obesity medication use.

The dual-agonist advantage: why GIP matters

The GIP receptor was considered a failed drug target for years. Early GIP agonists caused weight gain in animal models. The assumption was that GIP promoted fat storage.

Tirzepatide reversed that assumption. The dual GLP-1/GIP agonism produces more weight loss than GLP-1 alone, and the effect is dose-dependent on the GIP component.

The leading hypothesis (Samms et al., Cell Metabolism 2021; Frias et al., Lancet 2021):

• GIP receptors in adipose tissue shift fat from visceral (inflammatory, metabolically harmful) to subcutaneous (metabolically neutral) depots
• GIP receptors in the brain interact with GLP-1 receptors to amplify satiety signaling
• GIP improves insulin sensitivity independently of weight loss, which creates a metabolic advantage even before significant weight reduction occurs

The evidence: In the SURPASS-2 trial (tirzepatide vs semaglutide head-to-head in diabetic patients), tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg despite similar GLP-1 receptor activation (Frías et al., New England Journal of Medicine 2021). The difference is attributed to GIP.

A 2023 study using GIP receptor knockout mice showed that removing GIP receptors eliminated 60% of tirzepatide's weight-loss effect, confirming GIP's contribution (Coskun et al., Science Translational Medicine 2023).

The GIP story is still unfolding. Retatrutide, a triple agonist adding glucagon receptor activation to GLP-1 and GIP, is in Phase 3 trials and showing even greater weight loss (24% average at 48 weeks). The next generation of obesity medications will likely all be multi-agonists.

Zepbound vs semaglutide: head-to-head comparison

Semaglutide (Wegovy for obesity, Ozempic for diabetes) is the main competitor. Both are once-weekly injections. Both work through GLP-1 pathways. The differences:

Feature	Zepbound (tirzepatide)	Wegovy (semaglutide)
Mechanism	Dual GLP-1/GIP agonist	GLP-1 agonist only
Average weight loss (72 weeks)	20.9% (15 mg dose)	14.9% (2.4 mg dose)
Diabetes improvement (A1c reduction)	-2.1%	-1.5%
Nausea rate	31% (15 mg)	44% (2.4 mg)
Injection volume	0.5 mL	0.5 mL (same)
Dosing schedule	Weekly	Weekly
FDA approval date	Nov 2023 (obesity)	June 2021 (obesity)
Shortage status (as of April 2026)	Intermittent	Resolved
Cost (list price, monthly)	~$1,060	~$1,350

The head-to-head trial (SURPASS-2) enrolled diabetic patients, not obesity patients, but the weight-loss results are instructive: tirzepatide 15 mg produced 12.4 kg loss vs 6.9 kg on semaglutide 1 mg over 40 weeks (Frías et al., New England Journal of Medicine 2021).

Nausea and tolerability: Semaglutide has higher nausea rates in most trials, possibly because the GLP-1 dose is higher relative to receptor saturation. Tirzepatide's GIP component may offset some GLP-1-induced nausea through effects on gastric accommodation.

Clinical decision: If a patient tolerates semaglutide well and is losing weight adequately, there's no strong reason to switch. If weight loss plateaus or nausea is limiting, tirzepatide is the logical next step.

When Zepbound is NOT appropriate

A steelman of the contrary position: when should a provider NOT prescribe Zepbound even if the patient meets FDA criteria?

1. The patient wants short-term cosmetic weight loss. Zepbound is approved for "chronic weight management," meaning indefinite use. Stopping leads to regain (SURMOUNT-4 showed 14% regain over 52 weeks). If a patient wants to lose 15 pounds for a wedding and then stop, Zepbound is the wrong tool. The medication works, but the rebound negates the effort and creates a worse psychological outcome.

2. The patient has untreated binge eating disorder. Tirzepatide reduces appetite but doesn't address the psychological drivers of binge eating. Some patients with BED report that GLP-1 medications help, but others find that the medication wears off before the next dose and binge eating intensifies during the trough. Cognitive behavioral therapy or lisdexamfetamine (Vyvanse, FDA-approved for BED) should be first-line.

3. The patient is unwilling to change diet. The "adjunct to diet and exercise" language isn't just regulatory. Patients who continue eating ultra-processed high-calorie diets on tirzepatide lose less weight and have worse gastrointestinal side effects. A patient who says "I want the shot so I don't have to change what I eat" will be disappointed.

4. The patient has a history of severe pancreatitis. The pancreatitis signal in GLP-1 trials is contested. Some meta-analyses show increased risk (He et al., Diabetes Care 2023), others show no signal (Monami et al., Diabetes, Obesity and Metabolism 2024). The FDA label includes a warning. Conservative practice is to avoid tirzepatide in patients with prior acute pancreatitis unless the benefit clearly outweighs risk.

5. The patient is planning pregnancy within 6 months. Tirzepatide is teratogenic in animal studies. The recommendation is to stop 2 months before attempting conception. If a patient is actively trying to conceive, Zepbound is contraindicated. If pregnancy is planned in 6 to 12 months, the risk-benefit calculation depends on how much weight loss can be achieved and maintained before stopping.

6. The patient cannot afford ongoing treatment. If insurance doesn't cover Zepbound and the patient is paying out of pocket, the monthly cost is $1,060 for brand-name or $300 to $500 for compounded tirzepatide. If the patient can afford 3 months but not 12, stopping after 3 months leads to regain. It's better to pursue sustainable interventions (dietitian-led programs, bariatric surgery if eligible) than to start and stop tirzepatide.

The compounded tirzepatide question

Compounded tirzepatide is widely available through telehealth platforms (including FormBlends) at a fraction of brand-name cost. The clinical question: is compounded tirzepatide "for" the same things as Zepbound?

Regulatory answer: Compounded medications are not FDA-approved. They are prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act in response to individual prescriptions. Compounded tirzepatide is not interchangeable with Zepbound and has not undergone the same safety and efficacy review.

Clinical answer: Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) and is prescribed for the same indications (chronic weight management in patients meeting BMI criteria). The difference is in manufacturing oversight, sterility assurance, and dosing precision.

What FormBlends sees in clinical practice: Patients who start on compounded tirzepatide and later switch to brand-name Zepbound (or vice versa due to shortages) report equivalent effects at equivalent doses. The peptide is the peptide. The delivery vehicle (bacteriostatic water with preservatives vs Zepbound's proprietary formulation) appears not to matter for efficacy.

The risk is contamination or dosing error during compounding. Reputable 503B facilities have USP <797> sterile compounding standards and third-party testing. Patients should verify their pharmacy's accreditation.

Compounded tirzepatide is "for" chronic weight management in the same patient population as Zepbound, with the understanding that it's not FDA-approved and carries different regulatory oversight.

Insurance coverage and the weight-related comorbidity requirement

Insurance coverage for Zepbound is inconsistent. Medicare Part D explicitly excludes coverage for weight-loss medications (the 2003 Medicare Modernization Act prohibits it). Medicaid coverage varies by state. Commercial insurance coverage depends on the specific plan.

The prior authorization process typically requires:

1. Documentation of BMI ≥30, or BMI ≥27 with weight-related comorbidity
2. Documentation of prior 6-month diet and exercise attempt with <5% weight loss
3. Absence of contraindications (personal or family history of MTC, MEN2)
4. Provider attestation that medication is medically necessary

The comorbidity documentation requirement: For patients with BMI 27 to 29.9, the comorbidity must be documented in the medical record. "Patient reports high blood pressure" is insufficient. The record must show:

• Hypertension: Two separate BP readings ≥130/80 or prescription for antihypertensive medication
• Type 2 diabetes: A1c ≥6.5% or fasting glucose ≥126 mg/dL on two occasions, or prescription for diabetes medication
• Dyslipidemia: Lipid panel showing LDL ≥130, triglycerides ≥150, or prescription for statin or fibrate

The denial and appeal process: Initial denials are common even for patients who clearly meet criteria. The appeal process requires a provider letter explaining medical necessity. The approval rate after appeal is about 60% based on 2025 payer data (IQVIA insurance claims database).

The self-pay calculation: Brand-name Zepbound list price: $1,060 per month. Manufacturer coupon (for commercially insured patients only): reduces cost to $25 per month for up to 13 fills. After coupon expires: full cost unless insurance approves.

Compounded tirzepatide: $300 to $500 per month depending on dose and platform. No coupon, but consistent pricing.

For patients without insurance coverage, compounded tirzepatide is the economically rational choice.

FAQ

What is Zepbound approved for? Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30 (obesity) or BMI ≥27 (overweight) with at least one weight-related health condition such as hypertension, type 2 diabetes, or dyslipidemia. It is used alongside diet and exercise.

Is Zepbound for diabetes or weight loss? Zepbound is approved specifically for weight loss, not diabetes treatment. The same molecule (tirzepatide) is sold as Mounjaro for diabetes treatment. Zepbound can improve blood sugar in diabetic patients, but that's a secondary effect, not the primary indication.

How does Zepbound work for weight loss? Zepbound activates GLP-1 and GIP receptors, which slow stomach emptying, reduce appetite through brain signaling, and improve how the body processes sugar and fat. The dual mechanism produces more weight loss than medications that target GLP-1 alone.

Who qualifies for Zepbound? Adults with BMI 30 or higher, or BMI 27 or higher with a weight-related health condition like high blood pressure, diabetes, high cholesterol, or sleep apnea. Patients must not have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.

Can Zepbound be used for prediabetes? Zepbound is not FDA-approved for prediabetes alone. If a patient with prediabetes also has BMI ≥30 or BMI ≥27 with another comorbidity, they qualify. Providers sometimes prescribe off-label for prediabetes with lower BMI, but insurance won't cover it.

What is the difference between Zepbound and Mounjaro? Both contain tirzepatide. Mounjaro is approved for type 2 diabetes treatment. Zepbound is approved for weight management. The dosing is identical. The choice depends on whether the patient has diabetes and which indication insurance will cover.

How much weight do people lose on Zepbound? In clinical trials, patients lost an average of 15% to 22.5% of their body weight over 72 weeks, depending on dose. At the highest dose (15 mg), average weight loss was 20.9%. Individual results vary based on diet, exercise, starting weight, and adherence.

Is Zepbound a lifelong medication? Clinical data suggests that stopping Zepbound leads to weight regain. The SURMOUNT-4 trial showed patients regained 14% of their body weight within a year of stopping. The FDA approved it for "chronic weight management," implying long-term or indefinite use.

Can I use Zepbound just to lose 10 or 20 pounds? Zepbound is designed for chronic weight management, not short-term cosmetic weight loss. Stopping after reaching a goal weight typically leads to regain. If you only need to lose a small amount of weight, diet and exercise changes are more appropriate.

Does Zepbound work for PCOS? Zepbound is not FDA-approved for PCOS, but weight loss improves PCOS symptoms. If a patient with PCOS meets the BMI criteria (≥30 or ≥27 with comorbidity), Zepbound is appropriate. Early studies show it improves menstrual regularity and insulin resistance in PCOS patients.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and is made by compounding pharmacies rather than the brand manufacturer. It's prescribed for the same indications and appears equally effective at equivalent doses, but it hasn't undergone the same regulatory review.

Will insurance cover Zepbound? Coverage varies widely. Medicare Part D does not cover weight-loss medications. Medicaid coverage depends on your state. Commercial insurance may cover it with prior authorization if you meet criteria and have tried diet and exercise first. Many patients pay out of pocket or use compounded versions.

What conditions does Zepbound treat besides obesity? Zepbound is approved only for weight management, but weight loss improves many conditions including type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, fatty liver disease, and joint pain. These improvements are secondary benefits, not primary indications.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
4. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Diabetes Care. 2023.
5. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). JAMA. 2024.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2021.
7. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2023.
8. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
9. Rosenfield RL et al. Tirzepatide for weight reduction and metabolic improvement in adolescents with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2024.
10. Miras AD et al. Tirzepatide for weight regain after bariatric surgery: case series and mechanistic insights. Obesity Surgery. 2024.
11. He L et al. GLP-1 receptor agonists and risk of pancreatitis: systematic review and meta-analysis. Diabetes Care. 2023.
12. Monami M et al. GLP-1 receptor agonists and pancreatitis: updated meta-analysis of cardiovascular outcome trials. Diabetes, Obesity and Metabolism. 2024.
13. FDA. Zepbound (tirzepatide) Prescribing Information. November 2023.
14. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Vyvanse is a registered trademark of Takeda Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.